We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Leica Microsystems and Cell Signaling Technology Announce Partnership on Antibody Validation

Two hands shaking.
Credit: Pixabay

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Leica Microsystems and Cell Signaling Technology Announce Partnership on Antibody Validation"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Leica Microsystems and Cell Signaling Technology (CST) have announced a partnership to validate CST antibodies on the Cell DIVE multiplexed imaging solution. As an open multiplexing system, Cell DIVE offers unparalleled flexibility in antibody selection, allowing researchers to design custom antibody biomarker panels. Knowing that selected CST antibodies have been tested and verified using the Cell DIVE multiplexing workflow gives researchers the ability to move forward with confidence.


“By using validated antibodies with Cell DIVE, our open multiplexed imaging solution, researchers gain back precious time to focus on their scientific work,” says James O’Brien, vice president Life Sciences at Leica Microsystems. “Instead of spending time validating antibodies, the pre-validated antibodies from CST allow them to design their individual panels and obtain accurate and reproducible data quickly.”


Backed by a decade of research, the Cell DIVE iterative staining workflow enables the visualization of over 60 biomarkers on a single sample. Coupled with Leica-quality images of whole tissue sections at the single-cell level, Cell DIVE provides unparalleled spatial insights to deepen scientists’ understanding of the tissue microenvironment in key fields such as cancer research.


CST has a broad portfolio of antibodies, validated for immunohistochemistry (IHC) using a rigorous approach to ensure sensitivity and specificity, to detect key proteins in a variety of disease states. With this partnership, Leica Microsystems has tested CST antibodies conjugated to standard fluorophores and verified their compatibility with the Cell DIVE multiplexing workflow.


“Antibody specificity, reproducibility, and instrument compatibility are critical for researchers using spatial biology approaches. Our partnership with Leica Microsystems, and their Cell DIVE instrument, shows how we can work together to ensure efficient, accurate data collection, and empower scientific discoveries,” said Roby Polakiewicz, Chief Scientific Officer at Cell Signaling Technology.


The agreement with CST brings the total number of antibodies that are validated for the Cell DIVE workflow to 370+. For more information about Cell DIVE, please visit: https://www.leica-microsystems.com/products/light-microscopes/p/cell-dive/